MariMed Inc. (OTCMKTS:MRMD - Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 16,100 shares, a decrease of 66.1% from the August 15th total of 47,500 shares. Based on an average daily volume of 4,684,900 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 4,684,900 shares, the days-to-cover ratio is currently 0.0 days.
Analyst Ratings Changes
Separately, Zacks Research upgraded shares of MariMed from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Strong Buy".
View Our Latest Report on MRMD
MariMed Price Performance
Shares of MariMed stock remained flat at $0.14 on Wednesday. 519,162 shares of the company traded hands, compared to its average volume of 2,375,452. MariMed has a 1-year low of $0.07 and a 1-year high of $0.23. The company has a quick ratio of 0.36, a current ratio of 1.12 and a debt-to-equity ratio of 1.25. The business has a 50-day moving average of $0.12 and a two-hundred day moving average of $0.10. The stock has a market cap of $54.96 million, a P/E ratio of -4.67 and a beta of 3.01.
MariMed Company Profile
(
Get Free Report)
MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand.
Featured Articles
Before you consider MariMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MariMed wasn't on the list.
While MariMed currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.